NICE says no to Simponi for psoriatic arthritis
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has issued draft guidance rejecting Schering-Plough/Centocor's TNF inhibitor Simponi (golimumab) for treating active and progressive psoriatic arthritis in adults who have an inadequate response to previous disease modifying anti-rheumatic drug (DMARD) therapy.